Indaptus Therapeutics Stock Price

-0.02 (-0.23%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Indaptus Therapeutics Inc INDP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.23% 8.80 13:37:22
Open Price Low Price High Price Close Price Prev Close
8.70 8.66 9.26 8.82
Bid Price Ask Price Spread News
8.81 8.93 0.12 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,773 478,664 $ 8.96 $ 4,289,739 - 6.84 - 28.8299
Last Trade Time Type Quantity Stock Price Currency
13:37:53 1 $ 8.87 USD


Draw Mode:

Indaptus Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 47.57M 5.41M 1.61M $ - $ - -2.16 -3.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.02M 11.00%

more financials information »

Indaptus Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical INDP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.019.65737.938.691,959,208-0.21-2.33%
1 Month9.8528.82996.8410.8412,730,701-1.05-10.66%
3 Months10.1028.82996.8410.806,673,381-1.30-12.87%
6 Months10.1028.82996.8410.806,673,381-1.30-12.87%
1 Year10.1028.82996.8410.806,673,381-1.30-12.87%
3 Years10.1028.82996.8410.806,673,381-1.30-12.87%
5 Years10.1028.82996.8410.806,673,381-1.30-12.87%

Indaptus Therapeutics Description

Indaptus Therapeutics Inc is positioned to revolutionize the treatment of cancer and certain infectious diseases. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. Its pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.

Your Recent History
Indaptus T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.